Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy (Q38130485)

29 August 2017

title

Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy (English)

1 reference

29 August 2017

1 reference

Hualong Song

1

1 reference

29 August 2017

Shanshan Zhou

series ordinal

2

1 reference

29 August 2017

Rubing Wang

series ordinal

3

1 reference

29 August 2017

Shaoshun Li

series ordinal

4

1 reference

29 August 2017

publication date

21 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

8

1 reference

29 August 2017

issue

11

1 reference

29 August 2017

page(s)

1736-1749

1 reference

Hallmarks of Cancer: The Next Generation

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Environmental restrictions within tumor ecosystems select for a convergent, hypoxia-resistant phenotype of cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Negative feedback and adaptive resistance to the targeted therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Spindle assembly in animal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Targeted anti-mitotic therapies: can we improve on tubulin agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Kinesin superfamily motor proteins and intracellular transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Kinesin motor proteins as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Targeting the kinesin spindle protein: basic principles and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

A standardized kinesin nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

All kinesin superfamily protein, KIF, genes in mouse and human

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

How kinesin motor proteins drive mitotic spindle function: Lessons from molecular assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

The role of kinesin family proteins in tumorigenesis and progression: potential biomarkers and molecular targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

A genomic toolkit to investigate kinesin and myosin motor function in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Docking and rolling, a model of how the mitotic motor Eg5 works

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Phosphorylation by p34cdc2 protein kinase regulates binding of the kinesin-related motor HsEg5 to the dynactin subunit p150

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

The effect of monastrol on the processive motility of a dimeric kinesin-5 head/kinesin-1 stalk chimera

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Synthesis and differential antiproliferative activity of Biginelli compounds against cancer cell lines: Monastrol, oxo-monastrol and oxygenated analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

The structure of the ternary Eg5–ADP–ispinesib complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Cloning, enzyme characterization of recombinant human Eg5 and the development of a new inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

CPUYJ039, a newly synthesized benzimidazole-based compound, is proved to be a novel inducer of apoptosis in HCT116 cells with potent KSP inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Antitumor activity of a kinesin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Development and biological evaluation of potent and specific inhibitors of mitotic Kinesin Eg5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Novel ATP-competitive kinesin spindle protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Oncogenic role of kinesin proteins and targeting kinesin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Mitotic catastrophe: a mechanism for avoiding genomic instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

HR22C16: a potent small-molecule probe for the dynamics of cell division

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

A novel action of terpendole E on the motor activity of mitotic Kinesin Eg5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Mitosis is not a key target of microtubule agents in patient tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Kif15 cooperates with eg5 to promote bipolar spindle assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Development of therapeutic combinations targeting major cancer signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Microtubules and resistance to tubulin-binding agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Inhibition of Eg5 acts synergistically with checkpoint abrogation in promoting mitotic catastrophe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Mitotic drug targets and the development of novel anti-mitotic anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

The binding of vincristine, vinblastine and colchicine to tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Multicomponent therapeutics for networked systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Taxol suppresses dynamics of individual microtubules in living human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Understanding ribonucleotide reductase inactivation by gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Carboplatin delays mammary cancer 4T1 growth in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

The status of platinum anticancer drugs in the clinic and in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Genistein inhibited proliferation and induced apoptosis in acute lymphoblastic leukemia, lymphoma and multiple myeloma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Genistein-induced mitotic arrest of gastric cancer cells by downregulating KIF20A, a proteomics study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Targeting the cell cycle: a new approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Microtubule stabilising agents and ionising radiation: multiple exploitable mechanisms for combined treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

21 January 2018

The BCL-2 family reunion

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Imidazole-containing farnesyltransferase inhibitors: 3D quantitative structure-activity relationships and molecular docking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Farnesyltransferase inhibitor FTI-277 reduces mortality of septic mice along with improved bacterial clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Mitotic mechanics: the auroras come into view

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Trastuzumab treatment in multiple lines: current data and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Inhibitors of mitotic kinesins: next-generation antimitotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Enhanced stochastic optimization algorithm for finding effective multi-target therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Network target for screening synergistic drug combinations with application to traditional Chinese medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Systematic discovery of multicomponent therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Synergistic drug combinations tend to improve therapeutically relevant selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2FCMDC.201300228

21 January 2018

https://api.crossref.org/works/10.1002%2FCMDC.201300228

7 January 2021

A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

7 January 2021

Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

7 January 2021

7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

7 January 2021

Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201300228

7 January 2021

Identifiers

DOI

10.1002/CMDC.201300228

1 reference

29 August 2017

1 reference